Format

Send to

Choose Destination
Immunotherapy. 2013 Sep;5(9):923-5. doi: 10.2217/imt.13.87.

Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis.

Author information

1
University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology & Hepatology, MD, USA.

Abstract

The contribution of Th17 cells to the development of colitis is well described. The effector cytokines IL-17A and IL-17F have been proposed as potential therapeutic targets for the treatment of patients with inflammatory bowel disease. In a proof-of-concept study for the treatment of patients with Crohn's disease, secukinumab, a monoclonal antibody directed against IL-17A, was ineffective and associated with more adverse events than placebo. Wedebye Schmidt et al. propose that blockade of both IL-17A and IL-17F, rather than either cytokine alone, attenuates the development of colitis in a T-cell transfer model of experimental colitis. These findings suggest that combined blockade of IL-17A and IL-17F may be an effective strategy for the treatment of patients with inflammatory bowel disease.

PMID:
23998727
PMCID:
PMC3857957
DOI:
10.2217/imt.13.87
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center